How many 8-K filings has Entrada Therapeutics, Inc. filed?

Entrada Therapeutics, Inc. (TRDA) has 11 8-K (Current Event Report) filings on record, spanning Jan 2024 to May 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Entrada Therapeutics, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Entrada Therapeutics, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Entrada Therapeutics, Inc. (TRDA) — 8-K Filings

All 8-K filings from Entrada Therapeutics, Inc.. Browse 11 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (11)

8-K Filing — May 7, 2026
Entrada Therapeutics Files 8-K on Security Holder Vote — Jun 11, 2025 Risk: low
Entrada Therapeutics, Inc. filed an 8-K on June 11, 2025, to report on the submission of matters to a vote of its security holders. The filing does not contain
Entrada Therapeutics Appoints New CMO, Elects Director — Jun 3, 2025 Risk: medium
Entrada Therapeutics, Inc. announced on May 30, 2025, the appointment of Dr. Robert J. Mulcahy as Chief Medical Officer and the election of Ms. Sarah E. Kelly t
Entrada Therapeutics Reports Exit Costs — Apr 29, 2025 Risk: medium
On April 29, 2025, Entrada Therapeutics, Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The company, formerly known as Cyc
Entrada Therapeutics Files 8-K — Mar 24, 2025 Risk: low
Entrada Therapeutics, Inc. filed an 8-K on March 24, 2025, reporting on other events and financial statements. The company, formerly known as CycloPorters, Inc.
Entrada Therapeutics Files 8-K — Feb 24, 2025 Risk: low
Entrada Therapeutics, Inc. filed an 8-K on February 24, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures,
Entrada Therapeutics Files 8-K — Feb 3, 2025 Risk: low
Entrada Therapeutics, Inc. filed an 8-K on February 3, 2025, reporting on other events and financial statements. The company, formerly known as CycloPorters, In
Entrada Therapeutics 8-K Filing: Corporate Office Update — Jan 15, 2025 Risk: low
On January 15, 2025, Entrada Therapeutics, Inc. (TRDA) filed an 8-K report. The filing indicates the company's principal executive offices are located at One De
Roche Acquires Entrada Therapeutics for $4.3 Billion — Jun 24, 2024 Risk: medium
Entrada Therapeutics, Inc. announced on June 24, 2024, that it has entered into a definitive agreement to be acquired by Roche for approximately $4.3 billion. T
Entrada Therapeutics Files 8-K on Bylaws and Shareholder Votes — Jun 13, 2024 Risk: low
On June 13, 2024, Entrada Therapeutics, Inc. filed an 8-K report. The filing primarily concerns amendments to its articles of incorporation or bylaws, the submi
Entrada Therapeutics 8-K Signals Potential Leadership/Comp Changes — Jan 3, 2024
Entrada Therapeutics, Inc. filed an 8-K on January 3, 2024, reporting events from December 29, 2023. This filing indicates changes related to the 'Departure of

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX